Thus, aberrant activation of Jak2 by the V617F mutation enhances survival and proliferation of hematopoietic cells and plays a crucial role in pathogenesis the Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPN), such as polycythemia vera and essential thrombocythemia [11]. This evidence concerns the gene JAK2 and myeloproliferative disorder.